NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
CTT Pharma Shareholder Update: Manufacturing Plans, SEC Reporting, and Technology Advancements
TL;DR
CTT Pharma's patented micelle technology offers a competitive edge in drug delivery, with manufacturing plans for 2026 and SEC reporting to attract more investors.
CTT Pharma will file an S-1 for funding, use capital for manufacturing, hire regulatory experts, and locate a production facility in Q1 2026.
CTT Pharma's technology aims to improve oral drug delivery, potentially enhancing healthcare accessibility and offering a smoking cessation alternative through a Johns Hopkins partnership.
CTT Pharma's scientific paper on micelle strip technology will be published on December 15, 2025, increasing visibility and scientific understanding.
Found this article helpful?
Share it with your network and spread the knowledge!
The letter provides an update on CTT Pharma's progress toward manufacturing and commercializing its patented micelle thin-film technology, including plans to become an SEC reporting company, expand the team, and advance regulatory pathways.
The company plans to bring micelle encapsulated vitamins and other bioactive supplement strips, as well as nicotine oral strips, into manufacturing in 2026.
Becoming SEC reporting will bring additional transparency to the company and potentially attract a larger group of shareholders and investors, which is an important step for CTT Pharma's growth.
The company hopes to be SEC reporting before the end of 2025, but understands it could happen toward the beginning of Q1 2026.
The capital will be used toward manufacturing the company's patented micelle thin-film technology.
The company is adding regulatory experts to help move the technology through approval processes and plans to bring on someone with extensive experience in bringing commercial products to market.
The company anticipates identifying a building in the first quarter of 2026 and will then acquire the necessary equipment for production.
The partnership, part of an NIH grant using CTT's technology as a smoking cessation alternative, is still awaiting a funding decision for clinical trials, but manufacturing and commercialization plans are not dependent on this timing.
A scholarly review manuscript on micelle/oral dissolvable strip technology has been accepted for publication on December 15, 2025, which will increase visibility and understanding of the scientific principles behind CTT's platform.
Shareholders can expect a news release about the S-1 filing, will receive the scientific publication through a news release after December 15, 2025, and can look forward to a conference call in the first quarter to discuss progress. Contact information is provided at the end of the letter.
Curated from NewMediaWire
